Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Skin cancer (all types), drawn from the whole corpus: 9 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Non-melanoma skin cancer is missing from most cancer registries, so its true burden is unknown.
Melanoma incidence continues to rise in fair-skinned populations.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 5 changes by month →When this page itself was last checked or edited.
Neoadjuvant nivolumab produced pathological complete responses in a substantial share of resectable Merkel cell carcinomas, with durable responses; nivolumab also showed activity in recurrent cervical cancer.
Pembrolizumab and nivolumab approved for advanced melanoma, later moving to adjuvant and neoadjuvant use.
First hedgehog pathway inhibitor.
The first checkpoint inhibitor and the first BRAF inhibitor, the two routes that transformed melanoma.